ArticleAnnals of clinical and translational neurology2026
Olink Proteomics Analysis Reveals Heterogeneous Responses to FcRn Blockade in Anti-AChR Antibody-Positive Myasthenia Gravis: FGF-19 as a Novel Biomarker.
Article in Annals of clinical and translational neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveThis study aimed to systematically observe the clinical manifestations, immune cell subsets, and dynamic changes in serological indicators in patients with myasthenia gravis (MG) before and after efgartigimod (EFG) treatment.
methodsWe analyzed the baseline data, laboratory parameters, and lymphocyte subset proportions in MG patients before and after EFG treatment. Serum levels of 92 inflammation-related proteins were measured using Olink Target 96 proteomics in MG patients before and after EFG treatment. Validation was performed by enzyme-linked immunosorbent assay in an expanded cohort and followed by in vitro experiments to evaluate the effects of novel biomarkers on peripheral blood mononuclear cells from MG patients.
resultsFollowing EFG treatment, patients showed significant reductions in MG Activities of Daily Living (MG-ADL) scores and serum IgG levels, along with remodeling of immunocyte subset distribution. Olink proteomics analysis identified six differentially expressed inflammatory cytokines, among which fibroblast growth factor-19 (FGF-19) exhibited the most notable downregulation. Validation in an independent cohort demonstrated that serum FGF-19 levels were elevated and positively correlated with disease severity in MG patients. Furthermore, in EFG responders, the expression level of FGF-19 decreased after treatment. In vitro experiments demonstrated that FGF-19 promotes B-cell to plasma cell differentiation in MG patients.
interpretationEFG treatment can alleviate the clinical symptoms and decrease IgG levels in patients with MG. The downregulated expression following EFG treatment, along with the findings of in vitro experiments, indicates that FGF-19 may not only act as a biomarker for the efficacy of EFG, but also play a role in promoting the differentiation of B cells into plasma cells, thereby offering a novel target for therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.